CA2982911C - Methods of treating bacterial infections - Google Patents

Methods of treating bacterial infections Download PDF

Info

Publication number
CA2982911C
CA2982911C CA2982911A CA2982911A CA2982911C CA 2982911 C CA2982911 C CA 2982911C CA 2982911 A CA2982911 A CA 2982911A CA 2982911 A CA2982911 A CA 2982911A CA 2982911 C CA2982911 C CA 2982911C
Authority
CA
Canada
Prior art keywords
compound
meropenem
administration
dose
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2982911A
Other languages
English (en)
French (fr)
Other versions
CA2982911A1 (en
Inventor
David C. Griffith
Michael N. Dudley
Jeffrey S. Loutit
Olga Lomovskaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rempex Pharmaceuticals Inc
Original Assignee
Rempex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57144340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2982911(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rempex Pharmaceuticals Inc filed Critical Rempex Pharmaceuticals Inc
Publication of CA2982911A1 publication Critical patent/CA2982911A1/en
Application granted granted Critical
Publication of CA2982911C publication Critical patent/CA2982911C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2982911A 2015-04-24 2016-04-20 Methods of treating bacterial infections Active CA2982911C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562152668P 2015-04-24 2015-04-24
US62/152,668 2015-04-24
PCT/US2016/028437 WO2016172208A1 (en) 2015-04-24 2016-04-20 Methods of treating bacterial infections

Publications (2)

Publication Number Publication Date
CA2982911A1 CA2982911A1 (en) 2016-10-27
CA2982911C true CA2982911C (en) 2023-10-03

Family

ID=57144340

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2982911A Active CA2982911C (en) 2015-04-24 2016-04-20 Methods of treating bacterial infections

Country Status (8)

Country Link
US (2) US20160339045A1 (enExample)
EP (1) EP3285776B1 (enExample)
JP (2) JP6945452B2 (enExample)
CN (2) CN112755039A (enExample)
AU (1) AU2016252555A1 (enExample)
CA (1) CA2982911C (enExample)
ES (1) ES2942329T3 (enExample)
WO (1) WO2016172208A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
AU2014204045B2 (en) 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10385074B2 (en) 2014-05-05 2019-08-20 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2017290060B2 (en) 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
US12478606B2 (en) * 2017-01-09 2025-11-25 Melinta Subsidiary Corp. Methods of treating bacterial infections
AU2018345317B2 (en) * 2017-10-03 2024-10-24 Melinta Therapeutics, Inc. Methods of treating bacterial infections
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
CN112424209A (zh) 2018-04-20 2021-02-26 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
US12636297B2 (en) 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US12637481B2 (en) 2020-03-18 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
IL297458A (en) 2020-05-05 2022-12-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses
CN116098993B (zh) * 2022-11-17 2024-10-25 中国农业科学院特产研究所 一种狐、貉肺炎三联灭活疫苗及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof

Also Published As

Publication number Publication date
AU2016252555A1 (en) 2017-11-09
US20160339045A1 (en) 2016-11-24
CN112755039A (zh) 2021-05-07
WO2016172208A1 (en) 2016-10-27
JP2021143196A (ja) 2021-09-24
EP3285776A4 (en) 2019-01-23
EP3285776A1 (en) 2018-02-28
HK1249432A1 (en) 2018-11-02
US20190105337A1 (en) 2019-04-11
EP3285776B1 (en) 2022-12-21
CA2982911A1 (en) 2016-10-27
JP2018513188A (ja) 2018-05-24
JP7245289B2 (ja) 2023-03-23
JP6945452B2 (ja) 2021-10-06
CN107530364A (zh) 2018-01-02
ES2942329T3 (es) 2023-05-31

Similar Documents

Publication Publication Date Title
EP3285776B1 (en) Dosage regimen of vaborbactam and meropenem for treating bacterial infections in subjects with reduced renal function
US11007206B2 (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3139930B1 (en) Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3986419B1 (en) Boronic acid derivatives and therapeutic uses thereof
US12478606B2 (en) Methods of treating bacterial infections
HK1249432B (en) Dosage regimen of vaborbactam and meropenem for treating bacterial infections in subjects with reduced renal function
HK40051777A (en) Methods of treating bacterial infections
HK40097685A (en) Methods of treating bacterial infections with vaborbactam and meropenem
HK40018408B (en) Methods of treating bacterial infections with a combination of vaborbactam and meropenem
HK40018408A (en) Methods of treating bacterial infections with a combination of vaborbactam and meropenem
WO2014071155A1 (en) Therapeutic uses of tigemonam and carumonam
NZ795891A (en) Methods of treating bacterial infections

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210416

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250411

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250411

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260601